X
[{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Origo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agomab Therapeutics to Acquire Origo Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by AgomAb Therapeutics N.V
Filters
Companies By Therapeutic Area
Details:
AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in fibrotic indications.
Lead Product(s):
ORG-129
Therapeutic Area: Gastroenterology
Product Name: AGMB-129
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 02, 2023
Details:
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers.
Lead Product(s):
ORG-129
Therapeutic Area: Gastroenterology
Product Name: AGMB-129
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pfizer Inc
Deal Size: $114.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
July 13, 2022
Details:
The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.
Lead Product(s):
ORG-129
Therapeutic Area: Gastroenterology
Product Name: ORG-129
Highest Development Status: Phase I
Product Type: Small molecule
Recipient:
Origo Biopharma
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
October 28, 2021
Details:
Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.
Lead Product(s):
AGMB-101
Therapeutic Area: Immunology
Product Name: AGMB-101
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Redmile Group
Deal Size: $74.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
March 10, 2021